Welcome to our dedicated page for Regenerex Pharma news (Ticker: RGPX), a resource for investors and traders seeking the latest updates and insights on Regenerex Pharma stock.
Regenerex Pharma develops advanced wound closure and wound-care products for chronic and acute wounds. Its recurring company updates center on the QBx™ technology platform, the Accelerex sterile wound dressing, product manufacturing plans, clinical and regulatory development, and applications for diabetic ulcers, burns, pressure ulcers, and venous stasis ulcers.
Recent corporate developments also cover licensing, supply, and development agreements involving ovine collagen and nano-collagen for wound-care formulations, including collaboration with Holista Colltech Ltd. News about RGPX typically addresses product formulation, manufacturing supply, global commercialization rights, management structure, and regulatory work tied to medical-device and wound-healing products.
Regenerex Pharma (OTC: RGPX), a developer of advanced wound closure systems, has signed a binding supply and development agreement with Holista Colltech Ltd. of Perth, Australia. The agreement grants Regenerex exclusive worldwide rights to use Holista's proprietary ovine collagen technologies in wound care applications.
The agreement includes minimum purchase commitments starting at $50,000 in 2025, scaling to $9 million annually from 2028. Regenerex will conduct FDA clinical studies and regulatory approvals, while both companies will collaborate on new nano-collagen applications in wound care. Manufacturing will be conducted at Holista's facilities in Collie and Malaysia under GMP standards.
Regenerex Pharma (OTC: RGPX) has announced a strategic licensing agreement with Holista Colltech Ltd. to incorporate ovine nano-collagen into its QBx™ wound healing technology. The integration aims to enhance deep tissue regeneration through improved scaffolding facilitation and cell proliferation.
The company will utilize Holista's high-purity ovine collagen, sourced from disease-free Australian sheep, which offers advantages over traditional bovine or porcine collagen sources. The nano-collagen's ultra-small molecular size creates an optimal scaffolding matrix for cellular growth, particularly beneficial for deep tissue regeneration cases.
Summary not available.